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Background: In combined proton-carbon fixed-nozzle treatment facilities with raster scanning delivery, the
scattering of proton pencil beams caused by nozzle elements and the relatively large nozzle-to-isocenter distance
cause a beam broadening. This may pose limitations to the achievable dose conformity. One way to counteract this
effect is by delivering the treatment in a position closer to the nozzle than the room isocenter. Purpose of this
study was to assess the potential dosimetric benefit of such solution, in terms of dose conformity and normal tissue
sparing, in intensity-modulated proton therapy (IMPT) of intracranial tumors.
Material and methods: For 12 patients with intracranial lesions, IMPT-plans were created at two treatment
positions: nozzle-to-treatment-isocenter distance: 100 cm (room isocenter) and nozzle-to-treatment-isocenter
distance: 60 cm. The resulting plans were compared in terms of dose distributions, dose-volume histograms and
selected dosimetric indexes.
Results: With comparable target coverage, statistically significant normal tissue sparing was achieved through the
reduction of the distance between nozzle and treatment isocenter. The decrease in mean dose (Dmean) was 12.5%
to the whole brain, 16.2% to the brainstem, 9.7% and 15.4% to the temporal lobes, 10.0% and 12.9% to the
hippocampi, 11.8% and 12.5% to the optic nerves and 0.2% to the chiasm. The volume receiving at least 10% of the
prescribed dose (V10%) was reduced by more than 10% for most organs at risk (OARs). The maximum dose (Dnear-max)
values to most OARs remained without significant difference.
Conclusion: A reduced distance between nozzle and treatment isocenter leads to steeper lateral dose gradients and
significantly reduces the volume of OARs adjacent to the target, which receives low to intermediate doses. Technical
solutions shifting the treatment isocenter closer to the nozzle should be considered in clinical situations, where critical
OARs are adjacent to the beam channel and where the integral dose should be minimized.
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High precision radiotherapy is especially valuable in the
treatment of intracranial tumors, due to the direct vicin-
ity of critical structures. The finite range and precise
high-dose deposition towards range end (Bragg peak)
make proton beam therapy favorable for such treatments,
where a high degree of conformity is required [1,2].
Although to date only a few clinical studies comparing pro-
tons to high-energy photons have been conducted, dosi-
metric comparisons of treatment plans demonstrated a
reduced involvement of normal tissues [3-5]. Hence it is
expected, that the advantageous proton dose distributions
will result in reduced normal tissue morbidity.
In particular, application of the raster scanning tech-
nology, as opposed to passive beam scattering, offers
further potential advantage in terms of improved dose
conformity. A factor determining the achievable con-
formation is the size of the available beam, as smaller
beams allow forming steeper dose gradients. However,
when using raster scanning, proton beams undergo an
unavoidable spread, induced by multiple Coulomb scat-
tering and nuclear interactions within the beam delivery
and monitoring systems of the treatment nozzle. This ef-
fect is much more pronounced for protons as compared
to heavier ion species used in radiotherapy (e.g. carbon
ions) and results in marked beam broadening [6,7]. In
order to limit further degradation of the lateral penum-
bra, due to the geometrical beam divergence, the distance
between the nozzle and the patient should be kept as
short as possible.
However, in combined proton-carbon fixed-nozzle
raster-scanning treatment facilities, the geometry of the
treatment rooms typically represents a trade-off between
technical solutions in beam delivery, flexibility of patient
positioning and therapeutic requirements (e.g. degrees
of freedom of room positioning and imaging robotic
devices), resulting, in the example of our facility, in a
nozzle-to-isocenter distance of 100 cm. This leads to a
reduction of the pencil beam sharpness at the room
isocenter, possibly limiting the achievable dose distribution
conformity.
To minimize this problem, at our particle therapy
facility, application of the Extended Penumbra Reduc-
tion (EPR) technology (Siemens AG, Healthcare Sector,
Erlangen, Germany) has been planned. This technology, in-
tegrated in the planning and delivery systems, enables pa-
tient treatment at reference points that are closer to the
nozzle than the room isocenter and reduces the proton
pencil beam full-width-at-half-maximum (FWHM) in the
target by approximately 2–8 mm (see Figure 1) [8,9].
Since the greatest dosimetric advantages occur for lower
energies of the incident proton beams (see Figure 1), clin-
ical benefits are to be expected in the case of rather super-
ficially located tumors adjacent to critical structures, wheretumor control and normal tissue sparing are both primary
and uncompromising objectives. A typical situation, where
such highly conformal dose distribution is desired, is the
treatment of pediatric and/or benign intracranial tumors.
The purpose of this study was to assess the potential
dosimetric benefit of a solution, where the patient is
shifted towards the nozzle for treatment, in terms of the
dose conformity and normal tissue sparing in intensity-
modulated proton therapy (IMPT) of intracranial tumors,
in the context of the specific geometric limitations of a
fixed-nozzle facility.
Methods
Patient data
Twelve patients with intracranial tumors treated at the
Department of Radiotherapy and Radiation Oncology of
the University Medical Center of Marburg with photon
stereotactic radiotherapy (SRT) between 2003 and 2011
were selected for this planning study. Patient character-
istics are summarized in Table 1.
Written informed consent was obtained from the pa-
tient for the publication of this report and any accom-
panying images.
Imaging and treatment planning
Computed tomography (CT) and magnetic resonance
(MR) images were acquired for all patients in the supine
position. Image fusion guaranteed for precise target and
normal tissues delineation. The gross tumor volume (GTV)
was identified as the macroscopic tumor mass and the
planning target volume (PTV) was created by adding a
1 mm 3D-uniform margin to the GTV [10]. The median
PTV volume was 54.8 cm3 (range: 11.2-147.0 cm3). The
whole brain, brainstem, temporal lobes, hippocampi, optic
chiasm and optic nerves were outlined. The brain, brain-
stem, optic chiasm, optic nerves as well as the parts of
temporal lobes and hippocampi not overlapping with the
PTV were defined as organs at risk (OAR).
For the sake of result comparison within the study, a
common prescription was assigned to all cases, with a total
dose of 50.4 Gy(RBE) in 28 fractions to the PTV, using a
constant relative biologic effectiveness (RBE) factor of 1.1,
to convert between absorbed dose [Gy] and biologically
weighted dose [Gy(RBE)] [11]. The planning objective was
to deliver more than 95% of the prescribed dose to at least
95% of the PTV. Dose constraints to the OARs were speci-
fied according to available guidelines [12].
The treatment plans were generated with syngo® PT
Planning VA11 (Siemens AG, Healthcare Sector, Erlangen,
Germany). The beam directions were chosen individually
for each patient to avoid unnecessary dose, especially
to the optic nerves and hippocampi. For three patients,
a lateral parallel-opposed beam configuration was found
satisfactory from a clinical point of view, while for the
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Figure 1 Calculated spread of a proton beam from a nozzle geometry compatible with the ion beam therapy setup at the GSI [8,9]
and with recent Siemens combined ion therapy facilities, like the one at University Medical Center of Marburg. An initially parallel
particle beam enters a water absorber (patient) at 1 m distance from the nozzle exit. If the water absorber is shifted closer to the nozzle, the
width of the beam entering the water is reduced. The resulting difference in beam width in the patient for a 40 cm shift is explicitly marked
(red line) at three exemplary energies (50, 100 and 200 MeV).
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http://www.ro-journal.com/content/8/1/218remaining nine patients, isocentric couch rotations were
employed to achieve more favorable setups with oblique
cranial beams. For each patient, two plans were created,
adopting two different patient positions, defined by the
distance between nozzle and the treatment isocenter: 100
cm, placing the treatment isocenter in coincidence to the
room isocenter, and 60 cm, shifting the treatment isocenter
40 cm towards the nozzle and away from the roomTable 1 Patient characteristics
Number of patients 12
Gender
male/female 3/9
Age (y)
median 14
range 3-76
Tumor type
germinoma 1
recurrent medulloblastoma 1
optic glioma 2
ependymoma 1
pilocytic astrocytoma 2
meningioma 5isocenter. These two distances are referred to, in the
remainder of the text, as dISO and dISO-40, respectively.
Both treatment isocenter positions (and all intermediate
positions) can currently be technically realized at our par-
ticle therapy facility.
The treatment planning system used for this study con-
tains a set of tabulated measured spot sizes in air, recorded
during commissioning and yielding a parameterization of
the envelope of the scattered proton beam. Hence spot
sizes that can be requested during treatment planning, cor-
rectly model effects of nozzle distance reduction, if this is
employed. The available pencil beam transversal widths
(spot sizes) are a function of the beam energy [13]. At our
facility, for proton beam energies in the range needed to
treat head tumors (50–220 MeV), the smallest available
spot sizes in air, expressed as the full width half maximum
(FWHM) range for the highest and lowest energy re-
spectively, range from 11 to 32 mm at dISO and from 8
to 22 mm at dISO-40. These spot sizes were used in com-
bination with a raster pitch of 3 mm and in-depth Bragg
peak spacing of 3 mm. No passive devices (ripple filter or
other absorbers) were used. An additional tolerance,
expressed as a 3D margin, was set, allowing the TPS to
place pencil beams outside the PTV, to ensure target
coverage and counteract high fluence spots on its border.
This margin was adjusted individually for each patient,
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values ranging 4-5 mm laterally, 2–3 mm proximally and
3–4 mm distally.
Evaluation
PTV coverage and dose conformity were assessed through
several dosimetric indexes: near maximum and near mini-
mum dose (Dnear-max, Dnear-min) [14], mean dose (Dmean)
and conformity index (CI) [15].
To assess the integral dose and OAR sparing, both
plans of each patient were compared in terms of dose
distributions, dose volume histograms (DVH) and se-
lected dosimetric indexes: Dnear-min, Dnear-max [14], Dmean
and the volume percentage receiving at least 10% (V10%),
60% (V60%), 80% (V80%) or 95% (V95%) of the prescribed
dose.
Statistical analysis and evaluation
For statistical comparisons a nonparametric paired-sample
Wilcoxon signed-rank test, with a significance level of 0.05,
was used. The calculations were performed with the R stat-
istical package [16].
Results
Target volume coverage
PTV coverage of all plans was adequate and consistent
with the ICRU guidelines [14]. Additionally, no signifi-
cant differences were observed in Dnear-min, Dnear-max,
Dmean and CI95% between the plans, regardless of the
distance to the nozzle, as presented in Table 2.
Normal tissue and OAR sparing
Figure 2 and Figure 3 illustrate in an exemplary case
that sparing of normal tissues was more effective at the
treatment position closer to the nozzle. Dose-volumeTable 2 Planning target volume coverage for treatment
plans prepared in two different room positions
Dosimetric index dISO dISO-40 p
Dmin [Gy(RBE)] 46.4 (44.9÷47.6) 46.0 (43.9÷47.1) 0.791
Dnear-min [Gy(RBE)] 48.5 (48.4÷48.9) 48.6 (48.5÷48.9) 0.068
Dmean [Gy(RBE)] 50.4 (50.3÷50.5) 50.4 (50.2÷50.5) 0.204
Dnear-max [Gy(RBE)] 52.2 (51.8÷52.6) 52.1 (51.7÷52.3) 0.021*
Dmax [Gy(RBE)] 53.8 (53.1÷55.7) 54.3 (53.1÷55.4) 0.126
CI95% [−] 0.69 (0.45÷0.81) 0.70 (0.49÷0.83) 0.042*
CI50% [−] 0.30 (0.19-0.41) 0.36 (0.22-0.47) 0.002*
Values are median (range) of patient cohort.
Abbreviations: RBE relative biological effectiveness, D(near-)min (near) minimum
dose, D(near-)max (near) maximum dose, Dmean mean dose, CIX% conformity
index of PTV coverage with X% of prescription dose, dISO nozzle-to-treatment-
isocenter 100 cm (treatment at room isocenter), dISO-40 nozzle-to-treatment-
isocenter 60 cm.
* statistically significant difference (p < 0.05 two-tailed Wilcoxon
signed-rank test).comparisons for the whole brain and selected OARs for
all 12 patients are shown in Table 3. In all cases, im-
proved sparing of OARs was achieved at the treatment
isocenter position closer to the nozzle (dISO-40). Statisti-
cally significant reduction of the integral dose and sub-
stantial sparing of the OARs in terms of Dmean, V2%, V10%,
V60% and V80% were achieved in the whole patient cohort
owing to the decreased pencil beam widths.
The median reduction of Dmean for a treatment closer
to the nozzle, as compared to a treatment at the room
isocenter, was 12.5% to the whole brain, 16.2% to the
brainstem, 9.7% to the left temporal lobe, 15.4% to the
right temporal lobe, 10.0% to the left hippocampus,
12.9% to the right hippocampus, 0.2% to the optic chi-
asm, 11.8% to the left optic nerve and 12.5% to the right
optic nerve. The reduction of Dmean was statistically sig-
nificant for all organs at risk (p ≤ 0.004), except the optic
chiasm.
The reduced distance between nozzle and patient,
resulted in a median V2% decrease by 15.2% for the
whole brain, 14.0% for the brainstem, 8.8% for the left
temporal lobe, 12.1% for the right temporal lobe, 0.9%
for the left hippocampus, 2.4% for the right hippocam-
pus, 11.0% for the left optic nerve, 14.3% for the right
optic nerve, while no reduction was observed for the
optic chiasm. All V2% reductions in OARs were statis-
tically significant (p ≤ 0.007). Also the V10%, V60% and
V80% were significantly reduced for all OARs (respectively
p≤ 0.007, p≤ 0.007 and p≤ 0.042), except the optic chiasm
(Table 3).
The maximum dose to OAR remained similar and
with statistically significant(p < 0.05) tissue sparing at the
reduced nozzle-to-patient distance in selected OARs
only, clearly because of the very close proximity, if not
direct contact, of most OARs with the PTV. Similarly, a
reduction of Dnear-max at the reduced nozzle distance
was observed only in a minority of cases and reached
statistical significance for selected OARs only: whole
brain (p = 0.013), left temporal lobe (p = 0.001), right
temporal lobe (p = 0.003), left hippocampus (p = 0.002)
and right hippocampus (p < 0.001).
Normal tissue sparing achieved with treatment at the
reduced distance between nozzle and patient varied be-
tween cases as reflected by the considerable range of dif-
ferences (Table 3).
Discussion
The main rationale for preferring proton radiotherapy
over modern photon techniques in selected clinical situ-
ations is the highly conformal dose distribution, with
steep dose gradients, enabling not only homogeneous
target coverage, but also excellent sparing of OARs and,
consecutively, reduced risk of normal tissue compli-
cations. To avoid deterioration of these excellent dose
a b
Figure 2 Dose distribution in a representative axial CT slice of a selected patient for the IMPT plans created using two distances
between nozzle and treatment isocenter: a) 100 cm (dISO) and b) 60 cm (dISO-40). The reduced distance between the nozzle and patient
leads to a sharper lateral dose fall-off, hence to improved target conformation.
Jelen et al. Radiation Oncology 2013, 8:218 Page 5 of 9
http://www.ro-journal.com/content/8/1/218localization properties of protons, in the particular treat-
ment room geometry of combined proton-carbon raster-
scanning treatment facilities, technical means should be
exploited to counteract beam broadening caused by proton
scatter. Consequently, we investigated the advantage of
beam delivery at reference points, which are closer to the
nozzle than the room isocenter. Rather than modeling the
effects in simple test target geometries, attention was
turned to the dosimetric consequences in a realistic clinical
set up.
The reduced nozzle-to-patient distance enabled treat-
ment planning with sharper lateral penumbra and resulted
in improvement of the dose conformity for all patients in-
cluded in this study, as reflected in values of the PTV
CI50% conformity index and in the moderate, but statisti-
cally significant, sparing of adjacent normal structures 0
 20
 40
 60
 80
 100
 0  10  20  30
V
ol
um
e 
[%
]
Dose [Gy(RBE)]
Figure 3 Dose-volume histograms of selected OARs of an exemplary
(dISO - dashed line) and nozzle-to-patient distance 60 cm (dISO-40 - soltypically affecting the Dmean while preserving the Dmax, and
in the reduction of the integral dose.
Improvements in dose conformity in individual patients,
by the reduced nozzle-to treatment isocenter distance, de-
pend on many factors like number of beams, individual pa-
tient geometry and the degrees of freedom in the beam
setup. The steepness of the dose gradient can be enhanced
by a reduced nozzle to patient distance. Therefore, in
geometries, where critical organs at risk are located in close
proximity of the beam path and directly adjacent to the tar-
get, a relevant reduction of the maximum dose to such
OAR cannot be expected. Volumes receiving lower doses
can however be reduced, partially to an extent, which
might lead to a clinical benefit. The critical structures typ-
ically accounted for during the treatment planning for cra-
nial lesions, namely brainstem, optic nerves and optic 40  50
PTV
whole brain
brainstem
chiasm
left temporal lobe
right temporal lobe
left hippocampus
right hippocampus
left optic nerve
right optic nerve
case for both IMPT plans: nozzle-to-patient distance 100 cm
id line).
Table 3 Normal brain tissue sparing dose-volume comparisons
Volume of interest/dosimetric index Absolute difference Relative percentage difference p
Whole brain
Dnear-max [Gy(RBE)] 0.1 (−0.4÷3.0) 0.3 (−0.7÷8.5) 0.013*
Dmean [Gy(RBE)] 1.0 (0.5÷1.6) 12.5 (9.2÷16.0) 0.001*
V1% [%] 6.9 (4.1÷8.6) 16.7 (10.4÷21.0) <0.001*
V2% [%] 6.3 (3.4÷7.6) 15.2 (10.2÷19.9) <0.001*
V10% [%] 4.0 (2.4÷5.0) 13.6 (8.0÷18.4) <0.001*
V60% [%] 1.1 (0.2÷2.0) 11.3 (6.4÷16.4) <0.001*
V80% [%] 0.4 (0.1÷1.2) 6.3 (2.0÷12.1) <0.001*
V95% [%] 0.0 (−0.3÷0.3) 1.3 (−3.8÷7.0) 0.212
Brainstem
Dnear-max [Gy(RBE)] 0.0 (−0.2÷1.1) 0.0 (−0.4÷2.1) 0.173
Dmean [Gy(RBE)] 2.9 (1.0÷5.0) 16.2 (2.6÷30.9) <0.001*
V2% [%] 9.6 (0.0÷22.5) 14.0 (0.0÷27.0) 0.002*
V10% [%] 7.9 (0.6÷20.1) 14.8 (0.6÷31.1) <0.001*
V60% [%] 5.5 (2.0÷8.8) 17.6 (3.8÷34.4) <0.001*
V80% [%] 2.5 (0.3÷6.7) 17.2 (0.5÷40.0) <0.001*
V95% [%] 0.6 (−0.6÷2.7) 9.1 (−14.4÷30.7) 0.017 *
Chiasm
Dnear-max [Gy(RBE)] 0.0 (−1.5÷4.07) 0.0 (−2.9÷9.9) 0.695
Dmean [Gy(RBE)] 0.1 (−1.2÷4.7) 0.2 (−2.5÷26.4) 0.077
V2% [%] 0.0 (0.0÷14.6) 0.0 (0.0÷15.8) 0.5
V10% [%] 0.0 (0.0÷13.6) 0.0 (0.0÷17.7) 0.185
V60% [%] 0.0 (0.0÷13.3) 0.0 (0.0÷59.9) 0.050
V80% [%] 0.0 (0.0÷7.0) 0.0 (0.0÷64.5) 0.030*
V95% [%] 0.0 (−5.1÷8.7) 0.0 (−158.5÷26.7) 0.147
Left temporal lobe
Dnear-max [Gy(RBE)] 1.1 (−0.1÷5.3) 2.7 (−0.2÷18.0) 0.001*
Dmean [Gy(RBE)] 1.3 (0.5÷2.7) 9.7 (5.8÷27.4) <0.001*
V2% [%] 6.2 (0.8÷15.4) 8.8 (0.8÷38.2) <0.001*
V10% [%] 4.7 (1.4÷9.7) 7.2 (1.5÷40.0) <0.001*
V60% [%] 1.2 (0.0÷5.5) 13.1 (0.0÷63.9) 0.002*
V80% [%] 0.4 (−0.0÷4.0) 11.3 (−2.0÷33.3) 0.003*
V95% [%] 0.0 (−1.4÷1.2) 5.7 (−28.9÷50.0) 0.380
Right temporal lobe
Dnear-max [Gy(RBE)] 0.6 (−0.2÷2.7) 1.9 (−0.4÷7.9) 0.003*
Dmean [Gy(RBE)] 2.3 (0.5÷3.0) 15.4 (7.0÷28.7) <0.001*
V2% [%] 7.1 (2.4÷16.5) 12.1 (2.5÷38.0) <0.001*
V10% [%] 4.5 (1.7÷12.9) 11.5 (2.0÷36.4) <0.001*
V60% [%] 2.7 (0.0÷6.9) 20.7 (0.0÷28.2) 0.002*
V80% [%] 0.6 (−0.0÷2.3) 10.2 (−4.8÷18.3) 0.003*
V95% [%] 0.0 (−0.8÷2.0) 0.0 (−10.3÷63.9) 0.207
Left hippocampus
Dnear-max [Gy(RBE)] 0.3 (−0.1÷4.4) 0.7 (−0.3÷76.6) 0.002*
Dmean [Gy(RBE)] 1.9 (0.3÷5.3) 10.0 (0.8÷81.8) 0.001*
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Table 3 Normal brain tissue sparing dose-volume comparisons (Continued)
V2% [%] 0.9 (0.0÷15.0) 0.9 (0.0÷85.4) 0.007*
V10% [%] 5.8 (0.0 ÷18.5) 6.6 (0.0÷93.6) 0.005*
V60% [%] 1.7 (−0.2÷12.0) 10.1 (−0.2÷21.7) 0.007*
V80% [%] 0.7 (0.0 ÷13.1) 9.9 (0.0÷42.8) 0.007*
V95% [%] 0.0 (−0.3÷5.0) 0.9 (−3.7÷44.7) 0.040*
Right hippocampus
Dnear-max [Gy(RBE)] 0.5 (0.0÷2.3) 1.0 (0.0÷100.0) <0.001*
Dmean [Gy(RBE)] 2.5 (0.1÷4.2) 12.9 (4.9÷100.0) <0.001*
V2% [%] 1.6 (0.0÷19.4) 2.4 (0.0÷98.1) 0.007*
V10% [%] 7.1 (0.0÷14.9) 9.5 (0.0÷19.0) 0.007*
V60% [%] 5.9 (−0.2÷22.1) 15.3 (−184.6÷42.4) 0.004*
V80% [%] 2.6 (−0.0÷9.1) 11.7 (−16.7÷75.3) 0.004*
V95% [%] 0.1 (−0.5÷7.5) 0.8 (−14.3÷62.3) 0.118
Left optic nerve
Dnear-max [Gy(RBE)] 0.1 (−0.9÷3.9) 0.2 (−2.0÷100.0) 0.153
Dmean [Gy(RBE)] 2.2 (−0.3÷4.0) 11.8 (−0.7÷100.0) 0.004*
V2% [%] 7.3 (0.0÷17.7) 11.0 (0.0÷59.4) 0.005*
V10% [%] 8.4 (0.0÷16.8) 13.7 (0.0÷49.1) 0.005*
V60% [%] 2.0 (0.0÷7.1) 5.9 (0.0÷26.1) 0.003*
V80% [%] 0.9 (−2.1÷4.7) 2.8 (−41.6÷20.0) 0.042*
V95% [%] 0.2 (−11.0÷2.1) 2.1 (−42.9 ÷40.6) 0.172
Right optic nerve
Dnear-max [Gy(RBE)] 0.1 (−0.6÷7.3) 0.3 (−1.2 ÷97.8) 0.050
Dmean [Gy(RBE)] 2.5 (0.0÷5.1) 12.5 (0.0÷100.0) 0.002*
V2% [%] 10.8 (0.0÷25.7) 14.3 (0.0÷56.7) 0.002*
V10% [%] 9.0 (0.0÷18.2) 13.2 (0.0÷38.1) 0.003*
V60% [%] 3.3 (0.0÷7.8) 11.6 (0.0÷48.3) 0.003*
V80% [%] 1.3 (0.0÷7.1) 8.4 (0.0÷42.4) 0.003*
V95% [%] 0.2 (−1.2÷3.4) 2.4 (−57.4 ÷52.3) 0.078
Values are median (range) of patient cohort.
Abbreviations: RBE relative biological effectiveness, Dnear-max, near maximum dose, Dmean mean dose, VX% percentage of the volume receiving at least X % of the
prescribed dose.
* statistically significant difference (p < 0.05 one-tailed Wilcoxon signed-rank test).
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probabilities and established tolerance doses [17]. In the
cohort of patients examined in our study, the optic appar-
atus was typically abutting the PTV and therefore, sharpen-
ing of the beam penumbra, reduced the mean dose (Dmean)
in the optic apparatus but in most of the cases did not in-
fluence the maximal dose (Dmax). Only in two patients the
Dmax recorded in the nervi optici was appreciably reduced.
In these cases, the considered structures were located lat-
erally to the PTV, in close vicinity but not adjacent to it.
In the brainstem, evidence exists concerning dose-
volume effects. Using conventional fractionation of 2 Gy/
fraction, the entire brainstem may be treated to 54 Gy withlimited risk of severe neurologic effects, while smaller vol-
umes (<10 cm3) may be irradiated to maximum doses of
59 Gy [18]. Reduction of the penumbra width might there-
fore be of the advantage as for high-dose treatments more
complex constraints on the brainstem are used, allowing
higher dose in the brainstem surface but employing stron-
ger restriction for the central part [18].
With improving conformity of new radiation tech-
niques resulting in enhanced tumor control and hence
prolonged survival, more data on late cognitive toxicities
became available. This as well as the possibility of better
sparing of adjacent healthy tissue unmatched by the con-
ventional treatment modalities put new aspects of the
Jelen et al. Radiation Oncology 2013, 8:218 Page 8 of 9
http://www.ro-journal.com/content/8/1/218quality-of-life of the long-term cancer survivors in the
focus resulting in definition of additional OARs. This as-
pect is of major importance in pediatric cases.
Increasing evidence exists, that besides reduction of vol-
umes of normal tissues receiving high doses, limiting
medium and low dose exposure has high relevance for pre-
vention of late radiation morbidity [19]. The risk of neuro-
cognitive impairment after cranial radiotherapy strongly
depends on dose volume effects, where the dose to brain
sub-volumes plays a crucial role. Sparing of temporal lobes
as well as hippocampi is of special relevance as preclinical
and clinical evidence suggests, that radiation dose received
by the neural stem cells of the subgranular zone in the
hippocampus plays a role in radiation-induced neurocog-
nitive decline, specifically memory recall especially in the
immature brain [20,21]. To date, no specific constraints
have been defined for these structures, however some evi-
dence of a dose-volume relationship was observed.
Merchant et al. [22] correlated dose-volume data of 5
sub-volumes (total brain, supratentorial brain, infra-
tentorial brain, and left and right temporal lobes) with
intelligence quotient (IQ) at follow-up. Exposure to the
supratentorial brain appeared to have the most signifi-
cant impact. Each Gy of exposure had a similar effect on
IQ decline, regardless of dose level. These results under-
line the importance of measures to reduce radiation dose
and treatment volume at all dose levels [22]. Blomstrand
et al. [21] estimated, that a reduction of the mean dose
to both hippocampi from 20.7 Gy to 18.0 Gy limits the
risks for developing memory impairment from 47% (95%
confidence interval, 21-69%), to 44% (95% confidence
interval, 21-65%). In our study, the beam directions were
chosen to assure best hippocampal sparing by rotating
the beams to pass tangentially to the hippocampi when-
ever possible. Owing to this configuration, the reduction
of the mean dose to the hippocampi was in the same
range as in the described study, with a median reduction
of Dmean by 1.9 Gy(RBE) (0.3-5.3 Gy(RBE)) for the left
side and by 2.5 Gy(RBE) (0.1-4.2 Gy(RBE)) for the right
side. Hence, the reduction of the Dmean and other dose-
volume parameters (like V10%, V60%) is expected to be
beneficial in minimizing the side effects.
However, for skull-base tumor treatments, especially at
fixed-beam facilities, the temporal lobes are almost un-
avoidably in the beam channels. In this case, the advantage
of the patient-to-nozzle distance reduction manifests itself
solely in the reduction of the channel cross-section, and
therefore the volume of the organ involved and exposed to
low and medium doses, especially for larger tumors.
Finally, the Dmean as well as V10%, V2% and V1% of the
whole brain volume were significantly reduced, which
could be of special importance in the context of secondary
cancer induction as a late effect of radiation treatment. Re-
cent findings suggest, that decreasing the volume receivinglow to intermediate doses is decisive to decrease the rate of
secondary tumors, [23,24]. In the study by Diallo et al.
[23], 66% of secondary tumors occurred in the beam bor-
dering region (i.e. the area surrounding the PTV), where
normal tissue sparing can be improved, as demonstrated in
our study, with a reduced distance between nozzle and
treatment isocenter.
In centers equipped with a gantry, a greater effect can be
expected by a reduced nozzle-to-patient distance owing to
more degrees of freedom in choosing the beam directions.
In particular, as due to range uncertainties, in particle ther-
apy planning techniques are preferred, where the critical
structures are located at the lateral rather than the distal
edge of the beam [25]. This is especially important for
cyclotron based facilities with passive energy variation
obtained by insertion of range shifters, as it results with lar-
ger beam divergence at the nozzle exit. Therefore, the
existing literature puts stress on keeping the patient close
to the nozzle [25]. At the particle therapy center in Mar-
burg, with the current technical solution, shifting of pa-
tients by a maximum of about 40 cm towards the nozzle is
possible (the maximum depends on the isocentric angle).
In principle, further decreasing of the nozzle-to-patient
distance would allow for further reduction of the dose to
organs at risk. Additional improvements in conformity
might be achieved by adding a non-coplanar field, which is
however not preferable due to unnecessary involvement of
the normal brain tissue in the beam channel.
It should be noticed that shifting the treatment isocenter
closer to the nozzle puts further demands on quality assur-
ance (QA) procedures as mechanical, geometrical and
dosimetric (also patient specific QA) tests have to be
performed in at the new, shifted reference points. QA pro-
cedures for treatment planning and for patient positioning
must also be extended for the shifted treatment positions.
Especially, the image guided positioning verification re-
quires a careful QA, because in most cases it is not feasible
in the shifted treatment positions and therefore implies a
“blind” table movement between imaging and irradiation.
Laser control allowing for visual patient positioning con-
trol as a plausibility check prior irradiation is desirable. Ap-
propriate QA- and workflow procedures must therefore
ensure patient safety during daily clinical routine. Tech-
nical measures and software assistance, with appropriate
interlocks, are necessary to reliably avoid collision of
the devices and especially treatment at incorrect posi-
tions. All additional QA-requirements are however feas-
ible and technical support tools partly installed.
Conclusion
A reduced distance between the vacuum window of the
nozzle and the treatment isocenter leads to a steeper lat-
eral dose fall-off along the beam path and conse-
quently offers the possibility to further improve dose
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bined proton-carbon ion fixed-nozzle facilities with scan-
ning technology. Clinical benefit can be expected due to a
reduction of the volume of irradiated normal tissues, espe-
cially of the volume of OARs directly adjacent to the beam
channel, which receive low to intermediate doses. The
maximum dose to the OARs directly adjacent to the target
volume remains unchanged. The benefit for individual pa-
tients depends on the individual patient geometry, number
of beams and the degrees of freedom in the beam setup.
Use of this option should therefore be considered on an in-
dividual basis. Shifting of the treatment position closer to
the nozzle and out of the room´s isocenter requires appro-
priate quality assurance procedures to ensure safe and cor-
rect treatments.
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